XML 68 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information (Unaudited)
The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.
 
Three Months Ended
 
March 31,
2019
 
June 30,
2019
 
September 30,
2019
 
December 31, 2019 (1)
Total revenues
$
22,585

 
$
32,836

 
$
18,299

 
$
17,002

Operating loss
(50,216
)
 
(31,373
)
 
(44,637
)
 
(77,986
)
Loss from continuing operations
(52,900
)
 
(32,305
)
 
(49,054
)
 
(73,498
)
Net loss attributable to Precigen
(60,709
)
 
(38,766
)
 
(53,634
)
 
(169,215
)
Net loss from continuing operations attributable to Precigen per share, basic and diluted
$
(0.34
)
 
$
(0.21
)
 
$
(0.32
)
 
$
(0.47
)
Net loss attributable to Precigen per share, basic and diluted
$
(0.40
)
 
$
(0.25
)
 
$
(0.35
)
 
$
(1.09
)
(1)
During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).
 
Three Months Ended
 
March 31,
2018
 
June 30,
2018
 
September 30,
2018
 
December 31, 2018 (1)
Total revenues
$
37,160

 
$
42,771

 
$
30,055

 
$
41,192

Operating loss
(42,241
)
 
(34,807
)
 
(58,330
)
 
(268,119
)
Loss from continuing operations
(37,103
)
 
(52,120
)
 
(50,507
)
 
(274,587
)
Net loss attributable to Precigen
(46,165
)
 
(65,382
)
 
(57,324
)
 
(340,465
)
Net loss from continuing operations attributable to Precigen per share, basic and diluted
$
(0.28
)
 
$
(0.39
)
 
$
(0.38
)
 
$
(2.08
)
Net loss attributable to Precigen per share, basic and diluted
$
(0.36
)
 
$
(0.51
)
 
$
(0.44
)
 
$
(2.59
)

(1)
During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 5 and 6). The Company also recorded a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 18).